期刊文献+

2004年世界上市新药评述

Comments on world new chemical entities coming into the market in 2004
下载PDF
导出
摘要 新药的研发直接关系到企业的生存与发展,新药的上市备受医药界的关注。本文就2004年世界医药研发的状况、发展趋势以及2005年医药研发面临的挑战作一综述。针对2004年世界新药23个,按照其药效分类逐一进行简要介绍,以期为新药研究与开发提供参考。 Research and development of new chemical entities(NCEs) has direct link with the survival of the enterprises, and the marketing of NCEs attracts great attention of the medicine circles. The status quo of pharm industry of 2004 and challenges confronting pharm R&D in 2005 were reviewed in this paper. 23 launches of 2004 were briefly introduced according to their efficacy aiming to offer some advices to the pharm R&D.
作者 邹栩 陈玲
机构地区 中国药科大学
出处 《中国新药杂志》 CAS CSCD 北大核心 2005年第6期788-790,共3页 Chinese Journal of New Drugs
关键词 2004年 世界上市新药 新活性物质 2004 wrold new drugs new activity matirials
  • 相关文献

参考文献8

  • 1廖斌,丛欣,廖清江.2004年世界上市的新药[J].中国新药杂志,2005,14(4):501-501. 被引量:3
  • 2Lloyd L. Does lack of lanches spell end of expansion[ J ]. Scrip,2005,142: 24 - 25.
  • 3.新批准的抗肿瘤药.Pemetrexed[EB/OL].http://www.ebiotrade.com.,2004-06-15.
  • 4.中国癌症信息库国际抗癌新药信息网.恶性胸膜间皮瘤新药Alimta[ EB/OL ].http://www. bufotanine. com/otc/show. php?id= 170,2004-04-19.
  • 5.胰岛素治疗新发展[EB/OL].http://www.kmuh.org.tw/www/pharmacy/drug-info/info_3.html,2004-10-20.
  • 6陈小勇,彭润涛,江宇,张展,李述平,陈颖,张润峰.治疗糖尿病新药米格列奈[J].中国医药情报,2004,10(2):28-31. 被引量:21
  • 7.中国医药网信息中心.FDA批准骨髓病新药[EB/OL].http://www. yy114. com/news/content. asp? id= 9070,2004-08-15.
  • 8Merck Research Laboratories. The Merck Index[ M]. Thirteenth Edition. Whitehouse Station: Merck&CO. , INC, 2001. 3500.

二级参考文献7

  • 1Pratley RE,Foley JE ,Dunning BE. Rapid actingin sulinotropic agents :restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des, 2001 ; 7 (14) :1375-1397.
  • 2Malaisse WJ, Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm Metab Res, 1995,27:263-266.
  • 3Yamato T, Ishikawa K, Ojima K, et al. Effects of KAD-1229 on postgrandial hyperglycemia after oral meal load in STZ-induced diabetic rats. Jpn J Pharmacol, 2001 - 85 (suppll) : AbstP-602.
  • 4Misawa K, Ishikawa K, Oiima K, et al. Effects of KAD-1229,a nonsulfonylurea hypoglycemic agent,on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Pharmacology.2001,62 (2) :65.
  • 5Yamada N, Shigeta Y, Kaneko T,et al. Hypoglycemic effects and safety of a novel rapid-acting insulinotropic agent, KAD-1229, for NIDDM. Diabetes, 1996 ; 45 (Suppl 2) : Abst265.
  • 6Ohnota H,Koizumi T,Tsutsumi N,et al. Novel rapld-and short-acting hypoglycemic agent, a calcium (2S)-2-benzyl-3- (cis-hexahydro-2-isoindolinylcarbonyl ) propionate (KAD-1229) that acts on the sulfonylurea receptor:Comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther, 1994,269 : 489 - 495.
  • 7Ohnota H, Kitamura T, Kinukawa M, et al. A rapid-and short-acting hypoglycemic agent KAD-1229 improves post-prandial hypoglycernic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in steptozotocln-induced non-insulin-dependent diabetes mellitus rats. JPN J Pharmacol, 1996,71:315-323.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部